Congenital disorder of glycosylation type Id is an inherited glycosylation disorder based on a defect of the first mannosyltransferase involved in N-glycan biosynthesis inside the endoplasmic reticulum. Only one patient with this disease has been described until now. In this article, a second patient and an affected fetus are described. The patient showed abnormal glycosylation of several plasma proteins as demonstrated by isoelectric focusing and Western blot. Lipid-linked oligosaccharides in the endoplasmic reticulum, reflecting early N-glycan assembly, revealed an accumulation of immature Man 5 GlcNAc 2 -glycans in fibroblasts of the patient. Chorion cells of the affected fetus showed the same characteristic lipid-linked oligosaccharides pattern. However, the fetus had a normal glycosylation of several plasma proteins. Some fetal glycoproteins are known to be derived from the mother, but even glycoproteins that do not cross the placenta were normally glycosylated in the affected fetus. Maternal or placental factors that partially compensate for the glycosylation defect in the fetal stage must be proposed and may be relevant for the therapy of these disorders in the future. Inherited defects that affect the biosynthesis of N-or O-glycans are named congenital disorders of glycosylation (CDG) (1). N-linked glycans are attached to asparagine residues of the protein when the Asn occurs within the consensus sequence Asn-X-Ser/Thr. A precursor glycan (Glc 3 Man 9 GlcNAc 2 ) is first assembled in the endoplasmic reticulum on a lipid (dolichol) anchor via a pyrophosphate linkage (Glc 3 Man 9 GlcNAc 2 -PP-dolichol). The glycan is transferred from the anchor to nascent protein and is processed further in the endoplasmic reticulum and Golgi apparatus. O-glycans are attached to serine or threonine residues of the protein via a GalNAc-␣-Ser/Thr linkage and are elongated one sugar at a time; this process occurs in the endoplasmic reticulum and Golgi apparatus. The biochemical compartmentation of the assembly of N-and O-glycans gave rise to the classification of CDG into two subgroups, type I affecting the assembly of the precursor N-glycans on the lipid anchor in the endoplasmic reticulum and type II affecting the processing of the N-glycan after transfer to the protein (2). In recent years, 17 different CDG were characterized, and recently disorders of N-or O-glycosylation that are not yet part of the CDG nomenclature were described (3-5).
Inherited defects that affect the biosynthesis of N-or O-glycans are named congenital disorders of glycosylation (CDG) (1) . N-linked glycans are attached to asparagine residues of the protein when the Asn occurs within the consensus sequence Asn-X-Ser/Thr. A precursor glycan (Glc 3 Man 9 GlcNAc 2 ) is first assembled in the endoplasmic reticulum on a lipid (dolichol) anchor via a pyrophosphate linkage (Glc 3 Man 9 GlcNAc 2 -PP-dolichol). The glycan is transferred from the anchor to nascent protein and is processed further in the endoplasmic reticulum and Golgi apparatus. O-glycans are attached to serine or threonine residues of the protein via a GalNAc-␣-Ser/Thr linkage and are elongated one sugar at a time; this process occurs in the endoplasmic reticulum and Golgi apparatus. The biochemical compartmentation of the assembly of N-and O-glycans gave rise to the classification of CDG into two subgroups, type I affecting the assembly of the precursor N-glycans on the lipid anchor in the endoplasmic reticulum and type II affecting the processing of the N-glycan after transfer to the protein (2) . In recent years, 17 different CDG were characterized, and recently disorders of N-or O-glycosylation that are not yet part of the CDG nomenclature were described (3) (4) (5) .
In 1995, Stibler et al. (6) described two patients with severe psychomotor retardation and an abnormal isoelectric focusing (IEF) pattern of transferrin, suspecting a new subtype of CDG. The biochemical and molecular defect of one patient could subsequently be elucidated by Körner et al. (7) , who found a defect in the assembly of lipid-linked oligosaccharides (LLO) in the endoplasmic reticulum of the patient with an accumulation of Man 5 GlcNAc 2 -PP-dolichol. A missense mutation in the human ALG3 gene (8) (synonym: NOT56L, neighbor of tumorous imaginal discs-like protein) coding for dolichyl-PMan:Man5GlcNAc2-PP-dolichyl mannosyltransferase (EC 2.4.1.131) could be demonstrated (7) . Up to now, only this one patient with CDG Id has been described, and the clinical spectrum of the disease is not well defined. The clinical symptoms of CDG Id and the symptoms of the clinically very similar disorder CDG Ie are listed in Table 1 .
We describe a new patient and a fetus affected by CDG Id. IEF of transferrin and Western blots of serum proteins were performed. LLO analysis of fibroblasts of the patient and of chorion cells of the affected fetus revealed the presence of truncated LLO. Genomic sequencing of the ALG3 gene confirmed the diagnosis of CDG Id. Because a mutation that affected splicing was found, expression studies of the ALG3 gene using real-time PCR were performed to prove the physiologic significance of the mutation.
METHODS
IEF, SDS-PAGE, and Western blot. IEF of serum transferrin was performed with a PHAST electrophoresis system using a gel with a pH range of 5-7 (Pharmacia, Freiburg, Germany). Transferrin was immunoprecipitated and stained as described previously (9) .
Serum proteins were separated on 7.5 or 10% SDS polyacrylamide gels under reducing conditions and transferred to a PVDF membrane by Western blotting using standard procedures. After the membrane was blocked in 1% blocking solution (Boehringer, Mannheim, Germany) at 4°C overnight, it was incubated with polyclonal antibodies (1:5000) for ␣1-antitrypsin, antithrombin III, or ␣1-acid glycoprotein (Dako, Hamburg, Germany) for 1 h and washed three times in Tris-buffered saline with Tween 20 0.1% (pH 7.5). Blots were incubated with a peroxidase-conjugated secondary goat anti-rabbit antibody (Dako) for 30 min (1:2500). After washing in TBS, visualization of the protein bands was performed using a Chemiluminescence Blotting Substrate Kit (Hoffmann-La Roche Ltd, Basel, Switzerland).
Deglycosylation of plasma proteins. N-glycans were enzymatically released from total plasma proteins by incubation of 1 L of plasma with PNGaseF (NEB, Frankfurt, Germany) for 5 h. Subsequently, proteins were precipitated using ice-cold ethanol and air dried, and SDS electrophoresis buffer was added. Protein detection on Western blot was performed as described above.
Analysis of LLO. Chorion cells of the fetus and of a healthy control subject as well as dermal fibroblasts of the patient with CDG Id and a control subject were metabolically labeled with 100 Ci [2- 3 H]mannose per milliliter of labeling medium for 30 min and chased for 10 min in MEM. Oligosaccharides linked to dolichol were released, extracted, and analyzed by HPLC as described previously (10) . In brief, cells were harvested and extracted in chloroform/methanol 2:1 three times. The extract was dried under nitrogen and extracted with water. Subsequently, an extraction with chloroform/methanol/ water 10:10:3 was performed, and LLO were released from dolichol by mild acid hydrolysis for 20 min at 100°C in n-propanolol/0.1 N HCl (1:2). Glycans were detected by HPLC (Waters Alliance System; Waters, Eschborn, Germany) in an acetonitrile/water gradient using a Microsorb MV column (Varian, Darmstadt, Germany). For the identification of the peaks, commercially available fluorescence standards were used (Takara, Otsu, Shiga, Japan).
PCR. Genomic DNA was prepared from whole blood, fibroblasts, or chorion cells using a commercially available kit (Qiagen, Hilden, Germany). Genomic sequencing and direct sequencing of cDNA were performed using the primers described previously (11) . The samples were cycled 35 times using different conditions for amplification (protocols are available upon request).
Reverse transcription. RNA of chorion cells was extracted using a commercially available kit (RNeasy; Qiagen). RNA was quantified spectrophotometrically, and 1 g of total RNA was used for reverse transcription (firststrand cDNA synthesis kit; Roche, Mannheim, Germany) according to the manufacturer's instructions. cDNA was stored at Ϫ30°C until use.
Sequence analysis. DNA and cDNA were sequenced using an automated DNA sequencer (Applied Biosystems, Weiterstadt, Germany) and standard procedures.
Real-time PCR. Primers and PCR conditions used for real-time PCR of the ALG3 transcripts were described in detail previously (11) . In brief, real-time PCR was performed using the QuantiTect SYBR Green PCR Master Mix (Qiagen) with a real-time PCR cycler (ABI PRISM 7900HT Sequence Detection System; Applied Biosystems Foster City, CA). The primers spanned either the normal exon1/exon2 boundary or the truncated exon1del/exon2 boundary, thus exclusively amplifying either the normal transcript or the transcript carrying the deletion. One microgram of RNA was used for reverse transcription using random primers, and 10 ng of cDNA was applied. Each sample was cycled in duplicate.
The presence of primer dimers and unspecific PCR products was excluded by determination of the melting curve. 18S rRNA was used to normalize the samples for differences in the applied quantity of RNA and variations in cDNA synthesis efficiency. For amplification, TaqMan Universal PCR Master Mix and the predeveloped human 18S rRNA assay were used (Applied Biosystems).
The ABI Prism SDS 2.0 software (Applied Biosystems) was used to determine the cycle threshold (ct) for the samples. Relative amounts of copies were calculated by comparing their ct values according to Livak et al. (12) . Informed consent was obtained from all participants, and the study was approved by the Institutional Review Board.
RESULTS

Clinical phenotype.
The patient is a 6-y-old boy of Italian origin. His parents come from a small village in Sicily, where both families have lived for generations but were not known to be consanguineous. The family history is uneventful. After a normal pregnancy, the boy was born at 39 ϩ 3 wk with a body length of 48 cm (50th percentile), body weight of 4700 g (Ͼ97th percentile), and head circumference of 36 cm (75th percentile). Arthrogryposis multiplex was present at birth, 
ϩϩϩ, normal at birth (2) ϩϩ, normal at birth (5) Vision/Ophthalmology Optic atrophy (2), coloboma (1) Optic atrophy (1)(nd 4), Cortical blindness (4) MRI of the CNS Brain atrophy (2) delayed myelination (5), mild cerebral hypoplasia, cerebellar atrophy (inconstant) (4) Failure to thrive
n, normal; nd, not determined or not reported. ϩ to ϩϩϩ grade of symptoms. Number of patients showing specific symptoms in parentheses.
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including clubfeet and contractures of the hands. At the end of the first month of life, recurrent vomiting occurred and hypertrophy of the pyloric muscle was diagnosed. A muscle biopsy at 2 mo of age showed moderate fibrosis and hypertrophy of type 2c muscle. Starting at 2 mo of age, abnormal EEG recordings that initially showed a burst-suppression pattern were obtained. The patient was put on anticonvulsive treatment, starting with phenobarbital and later changed to vigabatrin even before the first seizures were clinically apparent. At 4 mo of age, the first episode of epileptic seizures was triggered by fever, followed by another one 4 mo later. The patient received a diagnosis of West syndrome and became seizurefree by treatment with valproate during his second year of life. Seizures resumed recently at the age of 5 y and are currently not controlled any more by valproate. Magnetic resonance imaging scans of the brain at 6 mo of age revealed cerebral atrophy (Fig. 1) . Hearing tests showed no abnormalities. At 6 y of age, the patient has severe vision impairment. He is unable to fixate on objects or to recognize them. He reacts to light. An electroretinography at 6 mo of age showed reduced amplitudes. The boy is unable to sit without support but can actively turn from back to front. He gropes for his toys and shows recognition when he touches them. There is no speech development. At 5 y of age, his body height was 98 cm (3rd percentile), his weight was 14.1 kg (3rd percentile), and his head circumference was 46.3 cm (Ͻ3rd percentile). There is little s.c. fat. The nasal bridge is broad and flat. The frontal teeth are close to each other, whereas wide spaces are present between the other teeth. The palate has a normal curving. There is no hepatosplenomegaly. Bilateral maldescensus testis is present. Patellar tendon reflexes are present, and Babinski sign is negative. Motor nerve conduction velocities are normal. The eyes show abnormal rotational and horizontal movements; light reaction of the pupils is present. There are contractures and clinodactyly of the distal phalanges of the fifth digits of the hands. A simian crease is present at the right palm. Nails of the second and third digits of the hands are small and dysplastic, and the fingers show a conical narrowing toward their ends. There are no feeding problems. Laboratory tests revealed normal values for plasma creatinine, liver transaminases, alkaline phosphatase, thyroid hormones, and urinary organic acids. Figure 1 shows pictures of the patient and some of the described physical stigmata at 5 y of age. Additional pictures and a movie of the patient can be found at our web site (http://cdg.uni-muenster.de).
IEF, SDS-PAGE, and Western blots. The mobility of transferrin separated by IEF depends on the amount of negatively charged terminal sialic acids of the oligosaccharide chains. Normally, two N-linked oligosaccharides each carrying two sialic acids are present on transferrin. IEF of the CDG Id patients revealed an additional band at the position of disialotransferrin. A shift of the apparent molecular weight of~2 kD in SDS-PAGE, the mass of one oligosaccharide chain, indicates the lack of at least one of the two complete oligosaccharides normally attached to transferrin (Fig. 2) . Analysis of ␣1-antitrypsin, antithrombin III, and ␣1-acid glycoprotein demonstrated the glycosylation defect for other glycoproteins as well (Fig. 2) .
Transferrin of an affected fetus (19 wk gestational age), sibling of the patient and likewise carrying the mutations in the Not56 gene, showed no obvious glycosylation abnormalities in the IEF and SDS-PAGE of transferrin (Fig. 2) . Because transferrin is known to partially cross the placenta from mother to fetus, Western blots of ␣1-antitrypsin, ␣1-acid glycoprotein, and antithrombin III were performed (Fig. 3) . Whereas the former two proteins revealed no glycosylation abnormalities in the fetus, the antithrombin III showed two bands indicating hypoglycosylation of the protein, although to a lesser extent than that in the patient with CDG Id (Fig. 3) . The enzymatic release of N-glycans from ␣1-antitrypsin, ␣1-acid glycoprotein, and antithrombin III by PNGaseF digestion and subsequent Western blotting proved that the protein pattern in Western blots is caused solely by differences in Nglycosylation and not influenced by protein heterogeneity or O-glycans (Fig. 3) .
LLO. Investigation of LLO after metabolic labeling was done to find disturbances in the stepwise assembly of the precursor N-glycan of the final structure Glc 3 Man 9 GlcNAc 2 on the lipid anchor dolichol in the endoplasmic reticulum. LLO were size-fractionated and analyzed by HPLC. Fibroblasts of a healthy control subject and the patient with CDG Id, as well as chorion cells of a control and chorion cells of the affected fetus, were investigated (Fig. 4) . In normal fibroblasts, the major fractions corresponded to the mature Glc 3 Man 9 GlcNAc 2 gly- can and smaller peaks corresponded to the intermediates of the Glc 3 Man 9 GlcNAc 2 synthesis. LLO of the patient with CDG Id showed an accumulation of immature Man 5 GlcNAc 2 with only small amounts of the mature Glc 3 Man 9 GlcNAc 2 glycan, indicating a disturbed assembly of LLO at the Man 5 level.
In control chorion cells, there is an increased amount of Man 9 GlcNAc 2 glycan intermediate relative to the mature Glc 3 Man 9 GlcNAc 2 glycan when compared with control fibroblasts using identical labeling conditions. The chorion cells of the affected fetus revealed a major peak at the Man 5 GlcNAc 2 position comparable to the patient's fibroblasts, but there were also more mature intermediates of the LLO assembly, indicating that the biochemical defect was present in the fetus but was slightly more leaky in chorion cells of the fetus than in fibroblasts of the patient (Fig. 4) .
Molecular investigations.
A homozygous mutation in exon 1 of the ALG3 gene of our patient resulted in aberrant splicing and the formation of a transcript that is proposed to code for a nonfunctional enzyme. The molecular findings of the patient described in this report are described in detail elsewhere (11) . The ALG3 gene of a fetus, sibling of the patient, was sequenced, and the homozygous mutation g.165CϾT (c.del.160 -196, p.Val54fsX66) was found, confirming that the fetus was also affected by CDG Id. Using real-time PCR, we found 98.8% of the ALG3 transcripts with aberrant splicing and only 1.2% of total ALG3 transcripts coding for the normal, fully active enzyme in the fetus, levels that were similar to the ratio found in fibroblasts and leucocytes of the patient, in whom 99.5% aberrant spliced ALG3 transcripts and 0.5% normal transcripts were found. The overall expression levels of 
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ALG3 in chorion cells of a healthy fetus and the fetus with CDG Id were identical to those in skin fibroblasts of a healthy control subject and the sibling with CDG Id when compared with the expression of two housekeeping genes (GAPDH and hALU; data not shown).
Because the accumulation of Man 5 GlcNAc 2 on dolichol is not specific for CDG Id and the clinical picture as well as the LLO phenotype were also compatible with CDG Ie (13-15) (Table 1) , we additionally sequenced the DPM1 gene and its subunits DPM2 and DPM3 after RT-PCR of the corresponding transcripts of our patient with CDG Id. A mutation in the coding region of the genes could be ruled out (data not shown).
DISCUSSION
CDG Id was discovered in 1999, but up to now, only one patient has been identified. The clinical picture had been described earlier by Stibler et al. (6) and was followed by the molecular characterization of the disease by Korner et al. (7) . Our patient has severe psychomotor retardation, secondary microcephaly, and seizures in common with the first patient. Additional symptoms include arthrogryposis multiplex present at birth and a severe vision impairment. Unlike the first patient, he has no coloboma of the iris. The clinical phenotype of CDG Id is very similar to the one found in CDG Ie. In fact, many of the symptoms present in the patient described above have been reported to be characteristic for CDG Ie. A comparison of symptoms of these two disorders is summarized in Table 1 . As shown by the symptoms listed in Table 1 , the distinction of CDG Id and Ie on the basis of clinical symptoms alone may well be impossible. Determination of serum creatine kinase might be helpful to distinguish CDG Id and Ie because it is normal in CDG Id but elevated in CDG Ie.
IEF and SDS-PAGE patterns of serum transferrin were different from CDG Ia. Asialotransferrin, which is commonly found in CDG Ia, was hardly detectable in both patients with CDG Id described so far.
As we could show previously (11) , an apparently silent mutation in the patient with CDG Id described here activates a cryptic splice site in exon 1, resulting in an almost exclusive usage of the activated cryptic splice site. The formation of a premature stop codon as a result of a deletion of 37 bp in the ALG3 transcripts implicates a loss-of-function mutation. The genetic background of the different ALG3 transcripts in the newly diagnosed fetus were identical to those described in the patient with CDG Id (11) . Even though there were slightly more normal ALG3 transcripts in the fetal chorion cells than in fibroblasts of the patient (1.2% in the fetus versus 0.5% in the patient), the amount of normal transcripts coding for the complete ALG3 protein was severely decreased. Accordingly, LLO of chorion cells that carried the mutation showed the metabolic block in the LLO assembly but also were slightly more leaky than LLO of the patient's fibroblasts. Abnormalities in the LLO pattern of chorion cells of a fetus who has CDG Id could be demonstrated here for the first time and suggests the suitability of LLO analysis for the diagnosis of CDG Id and most probably of other CDG type I in affected fetuses.
Plasma glycoproteins were markedly hypoglycosylated in the patient with CDG Id. However, neither transferrin nor ␣1-AT or ␣1-acid glycoprotein showed glycosylation abnormalities in the fetus at 19 wk of gestational age, although the LLO pattern as well as the molecular analysis clearly showed the defect in cells of the fetus (Fig. 4) . Similar results were obtained by Clayton et al. (16) in a fetus with CDG Ia. To perform prenatal diagnosis from cord blood of a fetus who is suspected to have CDG Ia, IEF of transferrin and ␣1-antitrypsin of a patient who had CDG Ia at 19 wk gestation was performed and showed normal mobility patterns (16) . Nevertheless, the patient turned out to have CDG Ia. Hypoglycosylation of serum proteins was not detectable before the third week of life. Normal glycosylation was not present in all plasma glycoproteins of the CDG Id fetus because antithrombin III revealed hypoglycosylation, although to a lower extent than in the sibling with CDG Id. Antithrombin III carries four N-glycans, and hypoglycosylation of patients with CDG was described to result in at least one additional band of lower molecular weight in SDS page (17) . However, 10 -15% of hypoglycosylated antithrombin III, termed AT III␤, is even common in healthy individuals (18) , and the normal ratio in the fetus is yet unknown. Thus the presence of AT III␤ does not necessarily represent a CDG phenotype.
A plausible explanation for the presence of normally glycosylated serum proteins in CDG Ia and CDG Id is the predominance of maternal proteins in the fetal serum. In fact, some maternal plasma proteins are known to cross the placenta in relevant amounts. IgG levels in neonatal and fetal blood arẽ 1.5-fold higher than in the maternal blood as a result of active placental transport (19) . There are variable data about the placental transport of transferrin, but although the fetal liver produces transferrin from the ninth week of gestational age, at least some transferrin crosses the placenta from mother to fetus (20, 21) . However, the placenta is tight for almost all other proteins, and even with high concentration gradients of Ͼ1:1000, diffusion levels are low (22, 23) . ␣1-Antitrypsin and other proteins that are found to be normally glycosylated in the affected fetus do not cross the placenta in relevant amounts. We conclude that there are factors partially compensating for the defect in the fetus. Expression patterns of glycosyltransferases are widely different during embryogenesis (24 -26) . Thus, a different expression pattern of enzymes as a result of different developmental regulation of genes contributing to the N-glycan synthesis might partially compensate for the defect in some tissues of the embryo and the fetus. In fact, de Jong et al. (27) could show an increase of hyperglycosylated transferrin in the maternal serum during pregnancy, an effect that could be detected in women who were taking oral contraceptives, too (28) , thus pointing to the relevance of hormones for hyperglycosylation. In fact, the genes of several glycosyltransferases contain hormone-responsive elements, nucleotide sequences within the promoter regions that are well conserved (29) .
Correction of the glycosylation defect seems to be restricted to glycoproteins synthesized in distinct organs, because in patients with CDG Ia, the CNS shows cerebellar hypoplasia, and fat pads and inverted nipples are already present at birth (16) . Because the biochemical origins of CDG Ia, a disorder 252 that is based on limited supply of GDP-mannose, and CDG Id, a disorder that affects an LLO assembly step, differ significantly, the basis of this phenomenon remains unclear. Nevertheless, it seems that maternal, fetal, or placental factors might normalize N-glycosylation of plasma proteins during pregnancy in biochemically different glycosylation disorders. In this context, it is important to question whether the gestational age or the time frame after delivery is decisive for the occurrence of hypoglycosylated transferrin in patients with CDG. The patient with CDG Ia described by Clayton et al. (16) was delivered at 35 wk of gestation, and carbohydrate-deficient glycoproteins became detectable in the second to third weeks of postnatal life. The same constellation was found in one of our patients who had CDG Ia and was delivered at 39 wk of gestation (data not shown). According to the half-life time of transferrin of~8 d, 2-3 wk after delivery, relevant amounts of hypoglycosylated transferrin would be expected in the patients with CDG independent of the gestational age if the delivery is decisive for the change of glycosylation. Thus, the limited data available suggest that plasma protein glycosylation is altered at the time of delivery.
We thus propose that the appearance of normally glycosylated plasma proteins is not autonomously regulated by the fetus but at least also by placental or maternal factors such as hormones that are withdrawn at the time of delivery. As an explanation for this phenomenon, developmentally regulated genes in the fetal liver are the most conceivable model. However, there is no enzymatic cascade that is known to be able to bypass the enzymatic block in CDG Ia and Id. Nevertheless, even later on in life, the hypoglycosylation of plasma proteins in patients with CDG Ia can be normal for prolonged periods of time (T.M., personal observation). It is tempting to speculate that this phenomenon might offer a possible approach for the development of therapeutic agents for these disorders.
